Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
Subscribe To Our Newsletter & Stay Updated
